Gastric cancer plasma miRNA biomarker combination, its application and early diagnosis kit for gastric cancer

Abstract

The invention discloses a plasma miRNA (micro-ribonucleic acid) biologic marker assemblage for gastric cancer and an application of the assemblage. The plasma miRNA biologic marker assemblage comprises the following plasma miRNAs: miR-190a, miR-331-5p, miR-362-3p and miR-369-3p, and miR-16 is taken as an internal reference. Good gastric cancer diagnostic value can be obtained through combined detection of miR-190a, miR-331-5p, miR-362-3p and miR-369-3p, and stomach neoplasm screening as well as auxiliary stomach neoplasm pathology identification and clinical diagnosis can be realized. MiR-16 is taken as the internal reference, so that the relative quantification accuracy during detection by the plasma miRNA biologic marker assemblage for the gastric cancer is improved greatly. An miRNA detection kit developed with the biologic marker assemblage as a target and applied to the gastric cancer has the advantages of rapid and convenient detection, high detection sensitivity and specificity, low cost and wide application range, can meet the requirements for detection of most patients with stomach neoplasms and is clinically verified to be high in prediction accuracy.

Description

technical field [0001] The invention belongs to miRNA and its application in the field of biotechnology, in particular to a plasma miRNA biomarker combination of gastric cancer and its application in gastric tumor screening, assisting gastric tumor pathological identification and clinical diagnosis. Background technique [0002] Gastric cancer is one of the common malignant tumors, and its mortality rate ranks third. Recent data show that gastric cancer ranks second in both the incidence of malignant tumors in males and the mortality rate of malignant tumors in females in urban my country. It is a major public health problem that seriously threatens human health and restricts economic and social development. Early diagnosis of gastric cancer means early intervention and treatment, which is of great significance to the prognosis of patients. At present, the diagnosis of gastric cancer mainly relies on endoscopic biopsy, which is invasive, brings pain to patients, and has hig...

AI Technical Summary

Problems solved by technology

In the detection of gastric cancer, Xiao Bin et al. invented a kit for detecting (or diagnosing) gastric cancer using miR-30b in tissues, which has a high sensitivity (up to 93.33%) in detecting (or diagnosing) gastric cancer using miR-30b in tissues advantages, but this invention does not mention the specificity of miR-30b in diagnosing gastric cancer, that is, the ability to distinguish normal people. Invasive operation, and if the primary gastric cancer tissue can be obtained, it can be diagnosed by pathology (Xiao Bin, Zou Quanming, Zhu Endong, Li Bosheng, Mao Xuhu, Li Na, Guo Gang. A kit for the diagnosis or detection of gastric cancer[ P]. Chongqing: CN102002532A, 2011-04-06.)

Further, Zhang Zhengdong et al. invented a kit for diagnosing gastric cancer using one or more of the four miRNAs miR-148a, miR-142, miR-26a and miR-195 in plasma / serum (Zhang Zhengdong, Wang Meilin, Kang Meiyun, Liu Sang, Chu Haiyan, Tong Na, Wu Dongmei, Zhao Qinghong, Gong Weida. Serum / Plasma MicroRNA Markers and Their Applications for Detecting Gastric Cancer [P]. Jiangsu: CN103773761A, 2014-05-07.), in this kit , U6 gene is used as an internal reference, but it has been reported in the literature that the expression of U6 gene in plasma is not stable, so using U6 gene as an internal reference gene to calculate the contents of the above four miRNAs may cause errors, which will affect the accuracy of diagnosis (Benz F ,Roderburg C,Vargas CD,et al.U6 is unsuitable fornormalization of serum miRNA levels in patients with sepsis or liverfibrosis.ExpMol Med.2013.45:e42;Xiang M,Zeng Y,Yang R,et al.U6 is not suitable endogenous control for the quantification of circulating microRNAs.BiochemBiophys Res Commun.2014.454(1):210-4.), in addition, this invention is to use one or more of the four miRNAs to diagnose gastric cancer, but the inventor did not specify when to use One miRNA diagnosis, when to use two, three or four miRNA combined diagnosis, also does not indicate when to use serum diagnosis, when to use plasma diagnosis, and if the results of using one miRNA to diagnose gastric cancer are different from those using multiple miRNAs When the results of combined miRNA diagnosis of gastric cancer are inconsistent, that is, if one miRNA diagnosis result is determined to be gastric cancer, and the results of multiple miRNA joint diagnosis of the same subject are determined to be non-gastric cancer, how to determine the diagnosis result at this time, in this invention None of them are explained, which will undoubtedly cause confusion to users

Images